Higher NT-proBNP levels have less prognostic importance in patients with HFpEF and AF than in those without.
Influenza activity was linked to increased heart failure hospitalizations in 4 influenza seasons.
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.
Additional transitional care services do not improve outcomes for heart failure patients discharged from the hospital.
Presence of microvascular disease in patients with both type 2 diabetes and cardiovascular disease increases the risk for heart failure and hospitalization for heart failure.
Optimizer Smart system approved for patients with chronic heart failure not eligible for tx with other devices.
Increased risk for heart failure seen in breast cancer survivors given trastuzumab rather than chemo alone.
Real-world data indicate that lower risk of heart failure hospitalization and death associated with use of sodium-glucose cotransporter-2 inhibitors is consistent in patients with T2D with both reduced and preserved ejection fraction.
Genetically predicted endogenous testosterone may have role in thromboembolism, heart failure, MI.
For patients with HFrEF, treatment with sacubitril/valsartan may aid in reducing the requirement for loop diuretics compared with enalapril.